Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 84.91 is 15% above its 1-year average of 73.85, near the high end of its 1-year range (55.88–90.16).
As of 2026-10-06T12:05:57.015Z.
Calculation as of: 2026-10-06T12:05:57.015Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 604c485faa117edd7b478e74db8828d7312282746a460099f8cc32b45e3ebf42
PE Ratio (84.91) = Close Price ($30.39) / Diluted TTM EPS ($0.36)
PE RATIO
84.91
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.67
median of 121 covered companies
CURRENT VS SECTOR MEDIAN
+230.78%
vs the sector median at left
Market Cap
$8.78B
PE Ratio
N/A
TTM Avg
41.90
3Y Avg
41.90
5Y Avg
41.90
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | $8.59B | 84.91 | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 23.16 | 22.16 | 45.57 | 45.57 |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.78B | N/A | 41.90 | 41.90 | 41.90 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.11B | N/A | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $9.35B | N/A | 552.62 | 552.62 | 552.62 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.80B | N/A | 44.08 | 44.08 | 44.08 |
| Insulet Corp. (PODD)vs › | $9.39B | 25.35 | 58.80 | 65.23 | 3594.22 |
| Hinge Health, Inc. (HNGE)vs › | $7.61B | 76.44 | 71.10 | 44.44 | 44.44 |
| Henry Schein, Inc. (HSIC)vs › | $9.60B | 24.56 | 23.93 | 23.91 | 21.89 |
| Bruker Corporation (BRKR)vs › | $9.72B | N/A | 54.08 | 39.03 | 41.91 |
At 84.9, P/E is above its 1-year median — higher than 79% of readings in its 1-year history.
1-year low
55.9
median
72.2
1-year high
90.2
Trailing P/E
84.9
Forward P/E
261.9
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$30.39
Forward EPS (Est.)
$0.12
Forward P/E
261.92
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-10-05 | 84.91 |
| 2026-10-02 | 79.07 |
| 2026-10-01 | 79.21 |
| 2026-09-30 | 85.58 |
| 2026-09-29 | 88.15 |
| 2026-09-28 | 88.71 |
| 2026-09-25 | 89.35 |
| 2026-09-24 | 90.16 |
| 2026-09-23 | 88.43 |
| 2026-09-22 | 87.93 |
| 2026-09-21 | 85.64 |
| 2026-09-18 | 83.77 |
| 2026-09-17 | 86.39 |
| 2026-09-16 | 78.82 |
| 2026-09-15 | 79.63 |
| 2026-09-14 | 72.79 |
| 2026-09-11 | 68.01 |
| 2026-09-10 | 67.17 |
| 2026-09-09 | 67.14 |
| 2026-09-08 | 69.35 |
| 2026-09-04 | 70.05 |
| 2026-09-03 | 70.75 |
| 2026-09-02 | 69.29 |
| 2026-09-01 | 69.24 |
| 2026-08-31 | 71.22 |
| 2026-08-28 | 71.61 |
| 2026-08-27 | 73.71 |
| 2026-08-26 | 74.94 |
| 2026-08-25 | 78.26 |
| 2026-08-24 | 73.01 |
| 2026-08-21 | 73.40 |
| 2026-08-20 | 68.68 |
| 2026-08-19 | 63.59 |
| 2026-08-18 | 58.59 |
| 2026-08-17 | 60.44 |
| 2026-08-14 | 60.91 |
| 2026-08-13 | 61.97 |
| 2026-08-12 | 62.20 |
| 2026-08-11 | 64.65 |
| 2026-08-10 | 65.38 |
| 2026-08-07 | 63.54 |
| 2026-08-06 | 55.88 |